Kloetzel, P. M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2, 179–187 (2001).
Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide identified by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976–7980 (1995).
Roche, P. A. & Furuta, Ok. The elegant facts of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15, 203–216 (2015).
Yewdell, J. W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952–961 (2003).
Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019).
Bianchi, V., Harari, A. & Coukos, G. Neoantigen-dispute adoptive cell therapies for most cancers: making T-cell products more deepest. Entrance. Immunol. 11, 1215 (2020).
Curran, M. A. & Glisson, B. S. Unique hope for therapeutic most cancers vaccines in the technology of immune checkpoint modulation. Annu. Rev. Med. 70, 409–424 (2019).
Haen, S. P., Löffler, M. W., Rammensee, H.-G. & Brossart, P. In direction of unusual horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595–610 (2020).
Kruger, S. et al. Advances in most cancers immunotherapy 2019: most modern traits. J. Exp. Clin. Cancer Res. 38, 268 (2019).
Christofi, T., Baritaki, S., Falzone, L., Libra, M. & Zaravinos, A. Contemporary views in most cancers immunotherapy. Cancers (Basel) 11, 1472 (2019).
Laumont, C. M. et al. World proteogenomic prognosis of human MHC class I-associated peptides derived from non-canonical studying frames. Nat. Commun. 7, 10238 (2016).
Sebestyen, E. et al. Sizable-scale prognosis of genome and transcriptome alterations in a few tumors unveils unusual most cancers-relevant splicing networks. Genome Res. 26, 732–744 (2016).
Zhao, Q. et al. Proteogenomics uncovers a foremost repertoire of shared tumor-dispute antigens in ovarian most cancers. Cancer Immunol. Res. 8, 544–555 (2020).
Ouspenskaia, T. et al. Thousands of unusual unannotated proteins amplify the MHC I immunopeptidome in most cancers. Preprint at bioRxiv https://doi.org/10.1101/2020.02.12.945840 (2020).
Chen, J. et al. Pervasive functional translation of noncanonical human originate studying frames. Science 367, 1140–1146 (2020).
Ilyas, S. & Yang, J. C. Landscape of tumor antigens in T cell immunotherapy. J. Immunol. 195, 5117–5122 (2015).
Caballero, O. L. & Chen, Y. T. Cancer/testis (CT) antigens: capacity targets for immunotherapy. Cancer Sci. 100, 2014–2021 (2009).
Tio, D. et al. Expression of most cancers/testis antigens in cutaneous melanoma: a systematic overview. Melanoma Res. 29, 349–357 (2019).
Schooten, E., Di Maggio, A., van Bergen En Henegouwen, P. M. P. & Kijanka, M. M. MAGE-A antigens as targets for most cancers immunotherapy. Cancer Treat. Rev. 67, 54–62 (2018).
D’Angelo, S. P. et al. Antitumor exercise associated with extended persistence of adoptively transferred NY-ESO-1 c259T cells in synovial. Sarcoma 8, 944–957 (2018).
Rapoport, A. P. et al. NY-ESO-1–dispute TCR–engineered T cells mediate sustained antigen-dispute antitumor ends up in myeloma. Nat. Med. 21, 914–921 (2015).
Robbins, P. F. et al. A pilot trial the exercise of lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-time length bid-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).
Laumont, C. M. & Perreault, C. Exploiting non-canonical translation to title unusual targets for T cell-essentially essentially based most cancers immunotherapy. Cell. Mol. Existence Sci. 75, 607–621 (2018).
Moreau-Aubry, A. et al. A processed pseudogene codes for a brand unusual antigen identified by a CD8+ T cell clone on melanoma. J. Exp. Med. 191, 1617–1623 (2000).
Li, L.-J., Leng, R.-X., Fan, Y.-G., Pan, H.-F. & Ye, D.-Q. Translation of noncoding RNAs: focal point on lncRNAs, pri-miRNAs, and circRNAs. Exp. Cell Res. 361, 1–8 (2017).
Charpentier, M. et al. IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens. Oncotarget 7, 59704–59713 (2016).
Roulois, D. et al. DNA-demethylating brokers aim colorectal most cancers cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
Chiappinelli, Ok. B. et al. Inhibiting DNA methylation causes an interferon response in most cancers by the exercise of dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).
Attermann, A. S., Bjerregaard, A. M., Saini, S. Ok., Gronbaek, Ok. & Hadrup, S. R. Human endogenous retroviruses and their implication for immunotherapeutics of most cancers. Ann. Oncol. 29, 2183–2191 (2018).
Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587–590 (2004).
Delong, T. et al. Pathogenic CD4 T cells in kind 1 diabetes acknowledge epitopes fashioned by peptide fusion. Science 351, 711–714 (2016).
Yewdell, J. W. & Holly, J. DRiPs fetch molecular. Curr. Opin. Immunol. 64, 130–136 (2020).
Welters, M. J. et al. Induction of tumor-dispute CD4+ and CD8+ T-cell immunity in cervical most cancers sufferers by a human papillomavirus kind 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14, 178–187 (2008).
Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013).
Skipper, J. C. et al. Mass-spectrometric overview of HLA-A*0201-associated peptides identifies dominant naturally processed kinds of CTL epitopes from MART-1 and gp100. Int J. Cancer 82, 669–677 (1999).
Wolf, B. et al. Safety and tolerability of adoptive cell therapy in most cancers. Drug Saf. 42, 315–334 (2019).
Purcell, A. W., Ramarathinam, S. H. & Ternette, N. Mass spectrometry-essentially essentially based identification of MHC-sure peptides for immunopeptidomics. Nat. Protoc. 14, 1687–1707 (2019).
Caron, E. et al. Analysis of main histocompatibility advanced (MHC) immunopeptidomes the exercise of mass spectrometry. Mol. Cell. Proteom. 14, 3105–3117 (2015).
Ritz, D., Kinzi, J., Neri, D. & Fugmann, T. Files-self reliant acquisition of HLA class I peptidomes on the Q exactive mass spectrometer platform. Proteomics 17, 1700177 (2017).
Gillet, L. C. et al. Centered recordsdata extraction of the MS/MS spectra generated by recordsdata-self reliant acquisition: a brand unusual belief for consistent and true proteome prognosis. Mol. Cell. Proteom. 11, O111.016717 (2012).
Brunner, A.-D. et al. Extremely-high sensitivity mass spectrometry quantifies single-cell proteome adjustments upon perturbation. Preprint at bioRxiv 2020.2012.2022.423933 (2020).
Tsou, C. C. et al. DIA-Umpire: complete computational framework for recordsdata-self reliant acquisition proteomics. Nat. Techniques 12, 258–264 (2015).
Muntel, J. et al. Surpassing 10 000 identified and quantified proteins in a single scurry by optimizing fresh LC-MS instrumentation and data prognosis technique. Mol. Omics 15, 348–360 (2019).
Gessulat, S. et al. Prosit: proteome-huge prediction of peptide tandem mass spectra by deep studying. Nat. Techniques 16, 509–518 (2019).
Croft, N. P. et al. Kinetics of antigen expression and epitope presentation at some point of virus an infection. PLoS Pathog. 9, e1003129 (2013).
Hassan, C. et al. Apt quantitation of MHC-sure peptides by application of isotopically labeled peptide MHC complexes. J. Proteom. 109, 240–244 (2014).
Croft, N. P., Purcell, A. W. & Tscharke, D. C. Quantifying epitope presentation the exercise of mass spectrometry. Mol. Immunol. 68, 77–80 (2015).
Tan, C. T., Croft, N. P., Dudek, N. L., Williamson, N. A. & Purcell, A. W. Express quantitation of MHC-sure peptide epitopes by selected response monitoring. Proteomics 11, 2336–2340 (2011).
Kapp, E. A. et al. An overview, comparison, and true benchmarking of various publicly on hand MS/MS search algorithms: sensitivity and specificity prognosis. Proteomics 5, 3475–3490 (2005).
Kapp, E. & Schutz, F. Overview of tandem mass spectrometry (MS/MS) database search algorithms. Curr. Protoc. Protein Sci. 49, 25.2.1–25.2.19 (2007).
Elias, J. E. & Gygi, S. P. Goal-decoy search technique for increased self perception in huge-scale protein identifications by mass spectrometry. Nat. Techniques 4, 207–214 (2007).
Zhang, J. et al. PEAKS DB: de novo sequencing assisted database look pretty and true peptide identification. Mol. Cell. Proteom. 11, M111.010587 (2012).
Shan, P. & Tran, H. Integrating database search and de novo sequencing for immunopeptidomics with DIA potential. J. Biomol. Tech. 30, S23 (2019).
Faridi, P., Purcell, A. W. & Croft, N. P. In immunopeptidomics we desire a sniper in location of a shotgun. Proteomics 18, e1700464 (2018).
Thompson, A. et al. Tandem mass tags: a peculiar quantification technique for comparative prognosis of advanced protein combinations by MS/MS. Anal. Chem. 75, 1895–1904 (2003).
Pfammatter, S. et al. Extending the comprehensiveness of immunopeptidome analyses the exercise of isobaric peptide labeling. Anal. Chem. 92, 9194–9204 (2020).
Ramarathinam, S. H. et al. A peptide-signal amplification technique for the detection and validation of neoepitope presentation on most cancers biopsies. Preprint at bioRxiv https://doi.org/10.1101/2020.06.12.145276 (2020).
Stopfer, L. E., Mesfin, J. M., Joughin, B. A., Lauffenburger, D. A. & White, F. M. Multiplexed relative and absolute quantitative immunopeptidomics unearths MHC I repertoire alterations prompted by CDK4/6 inhibition. Nat. Commun. 11, 2760 (2020).
d’Atri, V. et al. Including a brand unusual separation dimension to MS and LC–MS: what’s the utility of ion mobility spectrometry? J. Sep. Sci. 41, 20–67 (2018).
Pfammatter, S. et al. A unusual differential ion mobility instrument expands the depth of proteome coverage and the sensitivity of multiplex proteomic measurements. Mol. Cell. Proteom. 17, 2051–2067 (2018).
Pfammatter, S., Bonneil, E. & Thibault, P. Enchancment of quantitative measurements in multiplex proteomics the exercise of high-field uneven waveform spectrometry. J. Proteome Res. 15, 4653–4665 (2016).
Meier, F. et al. Online parallel accumulation-serial fragmentation (PASEF) with a peculiar trapped ion mobility mass spectrometer. Mol. Cell. Proteom. 17, 2534–2545 (2018).
Nesvizhskii, A. I. Proteogenomics: concepts, applications and computational techniques. Nat. Techniques 11, 1114–1125 (2014).
Zhang, M. et al. RNA improving derived epitopes feature as most cancers antigens to elicit immune responses. Nat. Commun. 9, 3919 (2018).
Wei, Z. et al. The landscape of tumor fusion neoantigens: a pan-most cancers. Anal. iScience 21, 249–260 (2019).
Löffler, M. W. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 11, 28 (2019).
Kalaora, S. et al. Exhaust of HLA peptidomics and complete exome sequencing to title human immunogenic neo-antigens. Oncotarget 7, 5110–5117 (2016).
Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes unearths sturdy results of protein abundance and turnover on antigen presentation. Mol. Cell. Proteom. 14, 658–673 (2015).
Khodadoust, M. S. et al. Antigen presentation profiling unearths recognition of lymphoma immunoglobulin neoantigens. Nature 543, 723–727 (2017).
Bassani-Sternberg, M. et al. Express identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
Binz, P. A. et al. Proteomics Requirements Initiative extended FASTA layout. J. Proteome Res. 18, 2686–2692 (2019).
Eng, J. Ok. & Deutsch, E. W. Extending comet for global amino acid variant and put up-translational modification prognosis the exercise of the PSI extended FASTA layout. Proteomics 72, e1900362 (2020).
Elias, J. E. & Gygi, S. P. Goal-decoy search technique for mass spectrometry-essentially essentially based proteomics. Techniques Mol. Biol. 604, 55–71 (2010).
Gupta, N., Bandeira, N., Keich, U. & Pevzner, P. A. Goal-decoy potential and groundless discovery charge: when things might maybe maybe well well also simply work disagreeable. J. Am. Soc. Mass Spectrom. 22, 1111–1120 (2011).
Tanner, S. et al. Enhancing gene annotation the exercise of peptide mass spectrometry. Genome Res. 17, 231–239 (2007).
Chong, C. et al. Constructed-in proteogenomic deep sequencing and analytics precisely title non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).
Laumont, C. M. et al. Noncoding areas are the principle supply of targetable tumor-dispute antigens. Sci. Transl. Med. 10, eaau5516 (2018).
Neat, A. C. et al. Intron retention is a supply of neoepitopes in most cancers. Nat. Biotechnol. 36, 1056–1058 (2018).
Attig, J. et al. LTR retroelement growth of the human most cancers transcriptome and immunopeptidome printed by de novo transcript meeting. Genome Res. 29, 1578–1590 (2019).
Kong, Y. et al. Transposable factor expression in tumors is expounded with immune infiltration and increased antigenicity. Nat. Commun. 10, 5228 (2019).
Shraibman, B., Melamed Kadosh, D., Barnea, E. & Admon, A. HLA peptides derived from tumor antigens prompted by inhibition of DNA methylation for pattern of drug-facilitated immunotherapy. Mol. Cell. Proteom. 15, 3058–3070 (2016).
Calviello, L. et al. Detecting actively translated originate studying frames in ribosome profiling recordsdata. Nat. Techniques 13, 165–170 (2016).
Erhard, F. et al. Improved Ribo-seq enables identification of cryptic translation events. Nat. Techniques 15, 363–366 (2018).
Ingolia, N. T. et al. Ribosome profiling unearths pervasive translation originate air of annotated protein-coding genes. Cell Salvage. 8, 1365–1379 (2014).
Slavoff, S. A. et al. Peptidomic discovery of speedy originate studying frame–encoded peptides in human cells. Nat. Chem. Biol. 9, 59–64 (2013).
Sarkizova, S. et al. A huge peptidome dataset improves HLA class I epitope prediction across many of the human inhabitants. Nat. Biotechnol. 38, 199–209 (2020).
Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more true epitope prediction. Immunity 46, 315–326 (2017).
Warren, E. H. et al. An antigen produced by splicing of noncontiguous peptides in the reverse mutter. Science 313, 1444–1447 (2006).
Dalet, A. et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl Acad. Sci. USA 108, E323–E331 (2011).
Michaux, A. et al. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a protracted peptide fragment followed by trimming. J. Immunol. 192, 1962–1971 (2014).
Hanada, Ok., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal most cancers antigen via put up-translational protein splicing. Nature 427, 252–256 (2004).
Liepe, J. et al. A huge part of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354–358 (2016).
Faridi, P. et al. A subset of HLA-I peptides are no longer genomically templated: evidence for cis- and trans-spliced peptide ligands. Sci. Immunol. 3, eaar3947 (2018).
Liepe, J., Sidney, J., Lorenz, F. Ok. M., Sette, A. & Mishto, M. Mapping the MHC class I–spliced immunopeptidome of most cancers cells. Cancer Immunol. Res. 7, 62–76 (2019).
Paes, W. et al. Contribution of proteasome-catalyzed peptide cis-splicing to viral focusing on by CD8+ T cells in HIV-1 an infection. Proc. Natl Acad. Sci. USA 116, 24748–24759 (2019).
Faridi, P. et al. Spliced peptides and cytokine-driven adjustments in the immunopeptidome of melanoma. Cancer Immunol. Res. 8, 1322–1334 (2020).
Mylonas, R. et al. Estimating the contribution of proteasomal spliced peptides to the HLA-I ligandome. Mol. Cell. Proteom. 17, 2347–2357 (2018).
Rolfs, Z., Solntsev, S. Ok., Shortreed, M. R., Frey, B. L. & Smith, L. M. World identification of put up-translationally spliced peptides with neo-fusion. J. Proteome Res. 18, 349–358 (2019).
Erhard, F., Dölken, L., Schilling, B. & Schlosser, A. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol. Res. 8, 1018–1026 (2020).
Vigneron, N., Ferrari, V., Stroobant, V., Abi Habib, J. & Van den Eynde, B. J. Peptide splicing by the proteasome. J. Biol. Chem. 292, 21170–21179 (2017).
Dalet, A., Vigneron, N., Stroobant, V., Hanada, Ok. & Van den Eynde, B. J. Splicing of far-off peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast recount factor-5. J. Immunol. 184, 3016–3024 (2010).
Henry, V. J., Bandrowski, A. E., Pepin, A. S., Gonzalez, B. J. & Desfeux, A. OMICtools: an informative itemizing for multi-omic recordsdata prognosis. Database (Oxford) 2014, bau069 (2014).
Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 replace. Nucleic Acids Res. 46, W537–W544 (2018).
Nesvizhskii, A. I. et al. Dynamic spectrum quality overview and iterative computational prognosis of shotgun proteomic recordsdata: against more efficient identification of put up-translational adjustments, sequence polymorphisms, and unusual peptides. Mol. Cell. Proteom. 5, 652–670 (2006).
Andreatta, M. et al. MS-Rescue: a computational pipeline to amplify the quality and yield of immunopeptidomics experiments. Proteomics 19, e1800357 (2019).
Rolfs, Z., Müller, M., Shortreed, M. R., Smith, L. M. & Bassani-Sternberg, M. Comment on ‘A subset of HLA-I peptides are no longer genomically templated: evidence for cis- and trans-spliced peptide ligands’. Sci. Immunol. 4, eaaw1622 (2019).
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, screen, and the future. Cell 168, 613–628 (2017).
Marcu, A. et al. The HLA Ligand Atlas. A useful resource of pure HLA ligands presented on benign tissues. J. Immunother. Cancer 9, e002071 (2019).
Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008).
Lang, D., Mascarenhas, J. B. & Shea, C. R. Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin. Dermatol. 31, 166–178 (2013).
Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the tainted with the factual. Nat. Rev. Immunol. 16, 207–219 (2016).
Rycaj, Ok. et al. Cytotoxicity of human endogenous retrovirus Ok–dispute T cells against autologous ovarian. Cancer Cells 21, 471–483 (2015).
Saini, S. Ok. et al. Human endogenous retroviruses possess a reservoir of T cell targets in hematological cancers. Nat. Commun. 11, 5660 (2020).
Mullins, C. S. & Linnebacher, M. Endogenous retrovirus sequences as a peculiar class of tumor-dispute antigens: an example of HERV-H env encoding sturdy CTL epitopes. Cancer Immunol. Immun. 61, 1093–1100 (2012).
Tu, X. et al. Human leukemia antigen-A*0201-restricted epitopes of human endogenous retrovirus W family envelope (HERV-W env) induce sturdy cytotoxic T lymphocyte responses. Virol. Sin. 32, 280–289 (2017).
Belgnaoui, S. M., Gosden, R. G., Semmes, O. J. & Haoudi, A. Human LINE-1 retrotransposon induces DNA atomize and apoptosis in most cancers cells. Cancer Cell Int. 6, 13 (2006).
Scott, E. C. et al. A hot L1 retrotransposon evades somatic repression and initiates human colorectal most cancers. Genome Res. 26, 745–755 (2016).
Ott, P. A. et al. An immunogenic deepest neoantigen vaccine for sufferers with melanoma. Nature 547, 217–221 (2017).
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-dispute therapeutic immunity against most cancers. Nature 547, 222–226 (2017).
Ebrahimi-Nik, H. et al. Mass spectrometry driven exploration unearths nuances of neoepitope-driven tumor rejection. JCI Insight 5, e129152 (2019).
Smith, C. C. et al. Replacement tumour-dispute antigens. Nat. Rev. Cancer 19, 465–478 (2019).
Jackson, R. et al. The interpretation of non-canonical originate studying frames controls mucosal immunity. Nature 564, 434–438 (2018).
Muller, M., Gfeller, D., Coukos, G. & Bassani-Sternberg, M. ‘Hotspots’ of antigen presentation printed by human leukocyte antigen ligandomics for neoantigen prioritization. Entrance. Immunol. 8, 1367 (2017).
Schittenhelm, R. B. et al. A complete prognosis of constitutive naturally processed and presented HLA-C*04: 01 (Cw4)-dispute peptides. Tissue Antigen. 83, 174–179 (2014).
Schuster, H. et al. The immunopeptidomic landscape of ovarian carcinomas. Proc. Natl Acad. Sci. USA 114, E9942–E9951 (2017).
Sarkizova, S. et al. A huge peptidome dataset improves HLA class I epitope prediction across many of the human inhabitants. Nat. Biotechnol. 38, 199–209 (2020).
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in Share Ib glioblastoma trial. Nature 565, 234–239 (2019).
Shraibman, B. et al. Identification of tumor antigens amongst the HLA peptidomes of glioblastoma tumors and plasma. Mol. Cell. Proteom. 17, 2132–2145 (2018).
Ternette, N. et al. Immunopeptidomic profiling of HLA-A2-obvious triple negative breast most cancers identifies capacity immunotherapy aim antigens. Proteomics 18, 1700465 (2018).